Study guide

5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management

UEMS European Board of Dermatovenereology Diploma Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Eligibility & Examination Regulations

1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition

2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology

2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns

3 Chapter 3: Dermatopathology & Diagnostic Procedures

3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy

4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology

4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance

5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease

5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders

6 Chapter 6: Hair, Nails & Pigmentary Disorders

6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation

7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease

7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses

8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease

8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease

9 Chapter 9: Autoimmune Bullous Diseases

9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis

10 Chapter 10: Eczematous Disorders, Urticaria & Allergology

10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy

11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis

11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses

12 Chapter 12: Paediatric & Genetic Dermatology

12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa

13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections

13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections

14 Chapter 14: Viral & Fungal Cutaneous Infections

14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses

15 Chapter 15: Sexually Transmitted Infections & Genital Infections

15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis

16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine

16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems

17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours

17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases

18 Chapter 18: Melanocytic Naevi & Melanoma

18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma

19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas

19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas

20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing

20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy

21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures

21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy

22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision

22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review

5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management

Key Takeaways Explain This Topic AI

Psoriasis affected about 3.9% of adults in the 27-country EADV Burden of Skin Diseases survey, and roughly 20% to 30% of patients develop psoriatic arthritis.

European consensus defines moderate-to-severe psoriasis by the "rule of tens": PASI above 10, body surface area above 10%, or DLQI above 10, with special sites able to upgrade severity.

The CASPAR criteria diagnose psoriatic arthritis with inflammatory joint, spine, or entheseal disease plus at least 3 points from psoriasis, nail dystrophy, negative rheumatoid factor, dactylitis, and juxta-articular new bone.

IL-17 inhibitors should be avoided in patients with inflammatory bowel disease; TNF-alpha monoclonal antibodies, ustekinumab, or IL-23 inhibitors are preferred when Crohn disease coexists.

Generalised pustular psoriasis is linked to IL36RN mutations, and the anti-IL-36 receptor antibody spesolimab is approved in the EU for treating GPP flares.

Last updated: September 2026

5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management

Psoriasis is one of the most common chronic diseases seen by dermatologists and a core General Dermatology topic. Questions usually test four things: recognising the clinical variant, scoring severity, spotting psoriatic arthritis, and choosing a systemic drug that suits the patient's comorbidities.

Pathogenesis and Triggers

Genetics: the strongest susceptibility locus is PSORS1 , containing HLA-C*06:02 , which is linked to early-onset (type I) and guttate disease.

Immunology: dendritic cells release IL-23 , which maintains Th17 cells . These produce IL-17A, IL-17F, and IL-22 , which drive keratinocyte proliferation and neutrophil recruitment. TNF-alpha amplifies the loop. This is why IL-17 and IL-23 blockers work so well.

Triggers: streptococcal throat infection (guttate psoriasis), physical trauma ( Koebner phenomenon ), stress, smoking, alcohol, obesity, HIV, and drugs. Classic drug triggers are lithium, beta-blockers, antimalarials, interferon, and rapid withdrawal of systemic corticosteroids (which can provoke pustular flares). Anti-TNF drugs can cause paradoxical psoriasis , often palmoplantar pustular.

Clinical Variants

Variant Key Features Points to Remember

Chronic plaque Well-demarcated, salmon-red plaques with silvery scale on extensors, scalp, sacrum; Auspitz sign About 80–90% of cases

Guttate Showers of small drop-like papules on the trunk in children and young adults Often 2–3 weeks after streptococcal pharyngitis; may clear or become chronic

Inverse (flexural) Glazed, red, scale-poor plaques in axillae, groins, submammary and intergluteal folds Differentials: candidiasis, erythrasma, tinea, intertrigo

Scalp Thick adherent scale extending just beyond the hairline Common first site; may cause temporary hair shedding

Nail Pitting and leukonychia (matrix); onycholysis, oil-drop spots, subungual hyperkeratosis, splinter haemorrhages (bed) Nail disease is a marker of psoriatic arthritis risk

Palmoplantar pustulosis Sterile yellow-brown pustules on palms and soles Strongly linked to smoking; can be part of SAPHO syndrome

Generalised pustular (GPP, von Zumbusch) Sudden sheets of sterile pustules on red skin, fever, leucocytosis Emergency; IL36RN mutations; triggers include steroid withdrawal and pregnancy (impetigo herpetiformis)

Erythrodermic More than 90% of body surface red and scaling Risk of fluid loss, hypothermia, infection, high-output heart failure

Acrodermatitis continua of Hallopeau Pustules on the distal fingers or toes, nail destruction Often resistant to treatment

Histology: confluent parakeratosis, Munro microabscesses in the stratum corneum, spongiform pustules of Kogoj , loss of the granular layer, regular acanthosis with thin suprapapillary plates, and dilated tortuous papillary capillaries.

Psoriatic Arthritis (PsA)

PsA affects roughly 20–30% of patients and usually follows the skin disease by about 10 years. Risk factors include nail disease , scalp and intergluteal or perianal involvement, and severe skin disease. Patterns include distal interphalangeal disease, asymmetric oligoarthritis, symmetric polyarthritis, spondylitis, and arthritis mutilans . Dactylitis ("sausage digit") and enthesitis (for example at the Achilles tendon) are typical.

CASPAR criteria: inflammatory articular disease (joint, spine, or entheseal) plus at least 3 points from:

  • Criterion Points
  • Current psoriasis 2
  • Personal history of psoriasis (if no current psoriasis) 1
  • Family history of psoriasis (if no personal history or current psoriasis) 1
  • Typical psoriatic nail dystrophy (pitting, onycholysis, hyperkeratosis) 1
  • Negative rheumatoid factor 1
  • Current dactylitis, or history recorded by a rheumatologist 1
  • Juxta-articular new bone formation on hand or foot radiographs 1

Dermatologists should ask about joint symptoms at every visit. Screening questionnaires such as the PEST (Psoriasis Epidemiology Screening Tool) help, and suspected PsA should be referred early to rheumatology.

Comorbidity

Moderate-to-severe psoriasis is associated with obesity, metabolic syndrome, type 2 diabetes, dyslipidaemia, hypertension, cardiovascular disease, non-alcoholic fatty liver disease, depression, and inflammatory bowel disease (especially Crohn disease) . Management includes screening for cardiovascular risk factors and mood, and advice on weight, smoking, and alcohol.

Measuring Severity

PASI (Psoriasis Area and Severity Index): 0 to 72, combining erythema, induration, and scale with area in four body regions.

BSA: the patient's palm with fingers is about 1% of body surface.

DLQI (Dermatology Life Quality Index): 10 questions, 0 to 30.

Rule of tens (European consensus, Mrowietz 2011): PASI > 10, BSA > 10%, or DLQI > 10 means moderate-to-severe disease. Mild disease by area can be upgraded when visible areas, scalp, genitals, palms and soles, or nails are significantly involved, or when itch is severe.

Treatment goals: the European consensus judged success by at least PASI 75, or PASI 50–75 with DLQI ≤ 5. Newer guidance increasingly uses absolute PASI targets (for example PASI ≤ 3) and DLQI 0–1.

European Treatment Ladder

Level Options Notes

Topical Vitamin D analogue plus corticosteroid (calcipotriol + betamethasone dipropionate fixed combination); corticosteroids; calcipotriol alone; dithranol; tar; calcineurin inhibitors for face and flexures (off-label) Fixed combination is standard first-line topical therapy

Phototherapy Narrowband UVB (311 nm); PUVA Limited by cumulative dose and skin cancer risk with PUVA

Conventional systemic Methotrexate, ciclosporin, acitretin, fumarates (dimethyl fumarate), apremilast (PDE4), deucravacitinib (TYK2) Acitretin is not immunosuppressive but is teratogenic for 3 years

Biologics TNF-alpha (adalimumab, etanercept, infliximab, certolizumab pegol); IL-12/23 (ustekinumab); IL-17 (secukinumab, ixekizumab, brodalumab, bimekizumab); IL-23 p19 (guselkumab, risankizumab, tildrakizumab) In the EU most biologics are licensed for patients who are candidates for systemic therapy

Matching the Drug to the Patient (EuroGuiDerm approach)

Psoriatic arthritis: methotrexate, TNF-alpha inhibitors, IL-17 inhibitors, IL-23 inhibitors, or ustekinumab. For axial disease, TNF or IL-17 blockers have the best evidence.

Inflammatory bowel disease: avoid IL-17 inhibitors , which can worsen or trigger Crohn disease. TNF monoclonal antibodies (adalimumab, infliximab), ustekinumab, or IL-23 inhibitors are preferred. Etanercept does not treat IBD.

Pregnancy wish: certolizumab pegol has minimal placental transfer. Avoid methotrexate, acitretin, and fumarates.

Heart failure (NYHA III–IV) or demyelinating disease: avoid TNF-alpha inhibitors.

Latent tuberculosis: IL-17 and IL-23 inhibitors carry a lower reactivation risk than TNF inhibitors; treat latent infection first either way.

Generalised Pustular Psoriasis

GPP is a medical emergency. It is linked to loss-of-function mutations in IL36RN (deficiency of the IL-36 receptor antagonist, DITRA). Spesolimab , an anti-IL-36 receptor antibody, is approved in the EU for GPP flares in adults. Other options include acitretin, ciclosporin, and infliximab, plus supportive care for fluid, temperature, and infection.

Loading diagram... Choosing psoriasis treatment by severity and comorbidity